{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:27:20Z","timestamp":1782030440714,"version":"3.54.5"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg sitagliptin (<jats:italic>n<\/jats:italic>= 60) or the placebo (<jats:italic>n<\/jats:italic>= 60) for 56 weeks and lifestyle modification in both groups. Laboratory and anthropometric outcomes were measured, and liver stiffness was assessed using a fibroscan. The primary outcome measures were changes from baseline in fibrosis scores and liver transferases. Out of 120 patients randomized into sitagliptin and placebo groups, 76 patients completed the trial, of whom 44 were in the sitagliptin and 32 in the placebo groups. Patients receiving sitagliptin showed a significant decrease in the fibrosis scores (<jats:italic>P<\/jats:italic>= 0.001). The reductions in the alanine aminotransferase (AST) (<jats:italic>P<\/jats:italic>= 0.036) and aspartate AST (<jats:italic>P<\/jats:italic>&amp;lt; 0.001) levels were also statistically significant. The effect of sitagliptin in reducing fibrosis scores was significantly greater in normal-weight and overweight individuals than in obese individuals (<jats:italic>p<\/jats:italic>= 0.036, and<jats:italic>p<\/jats:italic>= 0.018, respectively), whereas the effects of sitagliptin on AST levels were greater among overweight\/obese patients (<jats:italic>p<\/jats:italic>= 0.028, and<jats:italic>p<\/jats:italic>= 0.016, respectively). Sitagliptin reduced fibrosis scores and liver enzymes in NAFLD patients after 56 weeks of therapy. The changes in fibrosis scores were more prominent in patients with normal weight and overweight than obese patients, whereas the effects on AST levels were greater among overweight\/obese patients. Other randomized trials with larger sample sizes and longer treatment durations may be required before precise results can be reached.<\/jats:p><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p>[<jats:ext-link>https:\/\/www.irct.ir\/trial\/46140<\/jats:ext-link>], identifier [IRCT20140430017505N2].<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.937554","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T05:19:52Z","timestamp":1658985592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes"],"prefix":"10.3389","volume":"9","author":[{"given":"Azam","family":"Doustmohammadian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Nezhadisalami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Safarnezhad Tameshke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Motamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansooreh","family":"Maadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Farahmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoudreza","family":"Sohrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cain C. T.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Ajdarkosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Faraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Nikkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Sobhrakhshankhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1002\/cld.81","article-title":"Nonalcoholic fatty liver disease: definitions, risk factors, and workup.","volume":"1","author":"Puri","year":"2012","journal-title":"Clin Liver Dis."},{"key":"B3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0035-1562942","article-title":"Diagnosis and assessment of NAFLD: definitions and histopathological classification.","volume":"35","author":"Burt","year":"2015","journal-title":"Semin Liver Dis."},{"key":"B4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2212analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"key":"B5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10020270","article-title":"Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review.","volume":"10","author":"Rinaldi","year":"2021","journal-title":"Antioxidants."},{"key":"B7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","article-title":"Redefining fatty liver disease: an international patient perspective.","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/CM9.0000000000001263","article-title":"MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy.","volume":"134","author":"Xian","year":"2021","journal-title":"Chin Med J."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102677","article-title":"Prevalence of fatty liver disease and its associated factors among Jordanian patients with type 2 diabetes mellitus: a cross-sectional study.","volume":"68","author":"Almahmoud","year":"2021","journal-title":"Ann Med Surg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review.","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia."},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism."},{"key":"B14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease.","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040456","article-title":"Additive effect of non-alcoholic fatty liver disease on metabolic syndrome-related endothelial dysfunction in hypertensive patients.","volume":"17","author":"Perticone","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B16","article-title":"Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver.","volume":"5","author":"Foroughi","year":"2016","journal-title":"Adv Biomed Res."},{"key":"B17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep."},{"key":"B18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand J Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial).","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care."},{"key":"B21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.2337\/dc13-0496","article-title":"Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.","volume":"36","author":"Sell","year":"2013","journal-title":"Diabetes Care."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i15.2298","article-title":"Dipeptidyl peptidase-4: a key player in chronic liver disease.","volume":"19","author":"Itou","year":"2013","journal-title":"World J Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/13543776.2019.1632290","article-title":"Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).","volume":"29","author":"Hussain","year":"2019","journal-title":"Expert Opin Ther Patents."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i27.9090","article-title":"Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.","volume":"20","author":"Liu","year":"2014","journal-title":"World J Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"29207","DOI":"10.3390\/ijms161226156","article-title":"The dipeptidyl peptidase-4 inhibitor teneligliptin attenuates hepatic lipogenesis via AMPK activation in non-alcoholic fatty liver disease model mice.","volume":"16","author":"Ideta","year":"2015","journal-title":"Int J Mol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.5754\/hge11689","article-title":"Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin.","volume":"59","author":"Iwasaki","year":"2012","journal-title":"Hepato Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.endonu.2016.01.006","article-title":"Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: an observational, pilot study.","volume":"63","author":"D\u00edaz","year":"2016","journal-title":"Endocrinol Nutr."},{"key":"B29","first-page":"240","article-title":"Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.","volume":"75","author":"Yilmaz","year":"2012","journal-title":"Acta Gastro Enterol Belg."},{"key":"B30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial.","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol."},{"key":"B31","first-page":"323","article-title":"Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.","volume":"61","author":"Fukuhara","year":"2014","journal-title":"Hepato Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.3892\/mmr.2015.4329","article-title":"Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob\/ob male mice.","volume":"12","author":"Onoyama","year":"2015","journal-title":"Mol Med Rep."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27030727","article-title":"Sitagliptin is more effective than gliclazide in preventing pro-fibrotic and pro-inflammatory changes in a rodent model of diet-induced non-alcoholic fatty liver disease.","volume":"27","author":"Ren","year":"2022","journal-title":"Molecules."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S158053","article-title":"Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial.","volume":"10","author":"Alam","year":"2018","journal-title":"Hepat Med Evid Res."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis.","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1177\/0300060518793039","article-title":"Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups.","volume":"46","author":"Mahale","year":"2018","journal-title":"J Int Med Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jhep.2017.05.005","article-title":"Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.","volume":"67","author":"Wong","year":"2017","journal-title":"J Hepatol."},{"key":"B38","article-title":"Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"7","author":"Hashemi","year":"2016","journal-title":"Caspian J Int Med."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091987","article-title":"Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.","volume":"9","author":"Karlas","year":"2014","journal-title":"PLoS One."},{"key":"B40","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man.","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia."},{"key":"B41","first-page":"1","year":"1995","journal-title":"Physical Status: the Use and Interpretation of Anthropometry. WHO Technical Report Series No. 854"},{"key":"B42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.106.176158","article-title":"Diet and lifestyle recommendations revision 2006: a scientific statement from the American heart association nutrition committee.","volume":"114","author":"Lichtenstein","year":"2006","journal-title":"Circulation."},{"key":"B43","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1177\/1756283X16656735","article-title":"Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.","volume":"9","author":"Patel","year":"2016","journal-title":"Therap Adv Gastroenterol."},{"key":"B44","first-page":"232","author":"Machin","year":"2018","journal-title":"Sample Sizes for Clinical, Laboratory and Epidemiology Studies."},{"key":"B45","doi-asserted-by":"crossref","first-page":"290","DOI":"10.7326\/0003-4819-154-4-201102150-00016","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.","volume":"154","author":"Bian","year":"2011","journal-title":"Ann Int Med."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2018.0006","article-title":"Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease.","volume":"24","author":"Sayari","year":"2018","journal-title":"Clin Mol Hepatol."},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial.","volume":"23","author":"Joy","year":"2017","journal-title":"World J Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/met.2012.0128","article-title":"Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.","volume":"11","author":"Akaslan","year":"2013","journal-title":"Metab Syndr Relat Disord."},{"key":"B49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/iub.1709","article-title":"Significance of circulatory DPP4 activity in metabolic diseases.","volume":"70","author":"Nargis","year":"2018","journal-title":"IUBMB Life."},{"key":"B50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/gastro\/gox020","article-title":"Effects of lifestyle modification on liver enzyme and Fibroscan in Indian patients with non-alcoholic fatty liver disease.","volume":"6","author":"Paul","year":"2018","journal-title":"Gastroenterol Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.2337\/db07-1315","article-title":"Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.","volume":"57","author":"Muscelli","year":"2008","journal-title":"Diabetes."},{"key":"B52","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gut.38.6.916","article-title":"Attenuated GLP-1 secretion in obesity: cause or consequence?","volume":"38","author":"Ranganath","year":"1996","journal-title":"Gut."},{"key":"B53","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/jcph.1431","article-title":"Effects of sitagliptin on lipid profile in patients with type 2 diabetes mellitus after 7 years of therapy.","volume":"59","author":"Derosa","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002386","article-title":"Effects of sitagliptin on lipid profiles in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials.","volume":"95","author":"Fan","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"B55","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2337\/dc09-2062","article-title":"Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.","volume":"33","author":"Horton","year":"2010","journal-title":"Diabetes Care."},{"key":"B56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/jim-2017-000554","article-title":"Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.","volume":"66","author":"Dhir","year":"2018","journal-title":"J Investig Med."},{"key":"B57","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/bmj.322.7282.355","article-title":"Contamination in trials: is cluster randomisation the answer?","volume":"322","author":"Torgerson","year":"2001","journal-title":"BMJ."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/hep.22859","article-title":"SAFE biopsy: a validated method for large\u2212scale staging of liver fibrosis in chronic hepatitis C.","volume":"49","author":"Sebastiani","year":"2009","journal-title":"Hepatology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cgh.2010.03.025","article-title":"Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.","volume":"8","author":"Seeff","year":"2010","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/gut.2010.221382","article-title":"Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years.","volume":"60","author":"Roulot","year":"2011","journal-title":"Gut."},{"key":"B61","article-title":"Fibroscan (transient elastography) for the measurement of liver fibrosis.","volume":"8","author":"Afdhal","year":"2012","journal-title":"Gastroenterol Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.937554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T01:51:48Z","timestamp":1700877108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.937554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":61,"alternative-id":["10.3389\/fmed.2022.937554"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.937554","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"article-number":"937554"}}